FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:337-339 January 30, 1997 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

In chronic myelogenous leukemia (CML) the Philadelphia (Ph) chromosome originates from a reciprocal translocation, t(9;22)(q34;q11),¹ that generates a chimeric BCR-ABL gene.² The disease is incurable without bone marrow transplantation. In some cases, intensive chemotherapy^3,4 or treatment with interferon alfa can suppress the Ph-positive clone in the bone marrow,^5,6,7 but the detection of residual disease by the polymerase chain reaction (PCR) in patients with a complete cytogenetic response suggests incomplete eradication of these cells.⁸

Few cases of Ph-positive CML have been reported in which a long-term remission occurred without treatment.^9,10,11 We describe a patient with Ph-positive CML who entered a lengthy . . . [Full Text of this Article]

Case Report

Methods

Results

Discussion

Source Information

From the Third Department of Internal Medicine (M. Musashi, J.T., Y.G., S.M., Y.S., M. Morioka, K.S., M.A., and T. Miyazaki) and the Department of Microbiology (T. Minagawa), Hokkaido University School of Medicine; and the Chromosome Research Unit, Faculty of Science, Hokkaido University (S.A., T.Y.) — both in Sapporo, Japan.

Address reprint requests to Dr. Musashi at the Third Department of Internal Medicine, Hokkaido University school of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo 060, Japan.

References

This article has been cited by other articles:

• Clark, R. E., Dodi, I. A., Hill, S. C., Lill, J. R., Aubert, G., Macintyre, A. R., Rojas, J., Bourdon, A., Bonner, P. L. R., Wang, L., Christmas, S. E., Travers, P. J., Creaser, C. S., Rees, R. C., Madrigal, J. A. (2001). Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 98: 2887-2893 [Abstract] [Full Text]  
• Pinilla-Ibarz, J., Cathcart, K., Korontsvit, T., Soignet, S., Bocchia, M., Caggiano, J., Lai, L., Jimenez, J., Kolitz, J., Scheinberg, D. A. (2000). Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95: 1781-1787 [Abstract] [Full Text]